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Abstract
Background: It is important to understand the specific HPV genotype distribution in screen-detected lesions. HPV
Genotype is helpful for separating HPV-positive women at greater risk of cancer from those who can regress
spontaneously and for preventing cervical cancer at early stage. The aim of this study was to investigate the
high-risk HPV genotype distribution among cervical cytology abnormality in Pearl River Delta Region, Southern China
Methods: 5585 HPV-infected women were screened from 77069 women in Pearl River Delta Region. Information was
obtained from 3226 screened subjects through questionnaires and personal interviews. Exfoliated cervical cells were
collected by doctors for HPV test with MassARRAY (Sequenom, Sandiego, CA) technique based on the matrix-assisted
laser desorption/ionization time-of flight (MALDI-TOF) mass spectrometry (MS). The ThinPrep cytology test was performed
to screen for cervical cancer. Unconditional logistic was used to determine the most common HPV carcinogenic types.
Results: Of the 3226 HPV-positive samples tested, 1744 (54.1%) with normal cervical cytology, 1482 (45.9%) with abnormal
cytology. The five most common HPV types in this study were HPV16 (20.2%), HPV52 (17.1%), HPV58 (13.2%), HPV18
(9.5%), HPV6 (7.6%). Overall, HPV16 (OR = 10.5, 95% CI: 3.7 ~ 29.6), HPV33 (OR = 9.1, 95% CI: 2.8 ~ 29.2), HPV58 (OR = 6.3,
95% CI: 2.1 ~ 18.6), HPV31 (OR = 4.5, 95% CI: 1.3 ~ 15.5), multiple genotype infection (OR = 3.0, 95% CI: 1.7 ~ 14.7), especially
HPV16 and HPV33, increased the risk of cytology abnormalities.
Conclusions: HPV16, HPV31, HPV33, HPV58, and multiple HPV genotype infection increased the risk of cytology
abnormalities in Pearl River Delta Region and might be useful for the screening, preventing, treating, and monitoring of
pre-cancer lesions in southern China.
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Background
Cervical cancer is estimated to be the one of the leading
causes of cancer among women worldwide; approximately
530000 new cases and 275000 resultant deaths are
reported each year. About 85% of cervical cancer cases
occur in developing countries [1]. Infection with certain
high-risk human papillomavirus (HPV) types has a causal
and necessary role in the development of cervical cancer
and its precursor lesions [2,3]. More than 150 HPV types
have been identified [4], of the 30 high risk (HR) HPV
types, 15 are carcinogenic and infect the genitourinary
mucosa, which is highly associated with the development
of cervical cancer [5,6]. HPV16 is the most carcinogenic
type by far, followed by HPV18, 58, 33, 52, 45, 31, and 35;
together, these account for about 90% of cervical cancer
cases in Asia [7,8]. The low risk (LR) HPV types HPV6
and 11 are associated with low-grade cervical lesions and
about 90% of genital warts [9].
Besides HPV16 and HPV18, the next most common
types in all world regions, other high-risk carcinogenic
types, namely HPV31, HPV33, HPV45, HPV52, HPV58
and HPV35 have been reported with different distribution
across world regions. Sub- Saharan Africa with equally
HPV35 prevalence with HPV16, and the second most
common types were HPV31 in Europe, HPV58 in South
America, and HPV33 in Asia. Heterogeneity of HPV infec-
tion was significant across Asia, especially for HPV58 [10].
Notably, even high-risk HPV genotypes can contribute
to different progression of cervical disease [11]. A
meta-analysis from the IARC highlights the importance of
HPV type in the risk of progression to cancer, even from
HSIL by comparing the HPV type-distribution across
cervical lesions [12]. Furthermore, HPV type-distribution
has significant shifts across cervical lesions of increasing
severity [13], which indicate that there is great potential use
of HPV genotype not only in improving risk stratification
of women with HPV infection in cervical screening
programmes, but also in separating HPV-positive women
at greater risk of cancer from those who can regress
spontaneously.
There were about 58000 new cervical cases and
approximately 20000 deaths in China [14]. And the
widely variety of the incidence and mortality of cervical
cancer among different population, geographic area
and time period in China complicate the potential
HPV genotype attribution to cervical disease [14].
The Pearl River Delta Region (PRD) is located in
mid-southern coastal part of Guangdong, Southern
China, which with a total area over 56000 km2 and
with a population over 47 million. Notably, this area
accounts for 10% of China’s gross domestic product
(GDP) and over 80% of Guangdong’s GDP, which shows
highly concentration of economy activity. Genotyping can
be helpful for estimating the attribution of HPV genotype
in this area [15]. Thus, it is important to understand the
specific HPV genotype distribution in screen-detected
lesions which is helpful for preventing women with high
risk of cervical disease. The aim of this study was to inves-
tigate the HPV genotype distribution among cervical cy-
tology abnormality in PRD and to determine the most
prevalent genotype in cervical cytology disease grades.
Methods
Participants
The study was conducted between May 2011 and
November 2012 in Guangdong province, China. 5585
women were screened from 77069 women from nine
cities, of these 2359 were excluded. Subjects were
women between the ages of 18 and 68 years old (median
age: 38.0 years) from nine cities in the Pearl River
Delta region: Dongguan, Guangzhou, Huizhou, Jiangmen,
Qingyuan, Shenzhen, Zhaoqing, Zhongshan, and Zhuhai
(Figure 1). Eligible women were sexually active, had
an intact uterus, not pregnant, and had no history of
miscarriage, cervical cancer, medical treatment, or
surgery. Most women in the study had never been
screened for cervical cancer within the three preceding
years. All eligible women came to the Family Planning
Service Stations or nearby medical institutions of each
city, where the study was explained to each patient
and written consent for their participation was
obtained. Then the information and exfoliated cervical
cells were collected by doctors. The study protocol
was approved by the research ethics committee of
the Family Planning Research Institute of Guangdong
province.
HPV testing
Exfoliated cervical cell samples were collected from vaginal
swabs and conserved in 2.5 ml denaturation buffer (Qiagen,
Valencia). Total DNA from cervical cells was extracted
using the commercial magnetic beads kit (Chemagen,
Pekinelmer, Waltham, MA) according to the manufacturer’s
instructions. Then 16 HPV genotypes were detected,
including HPV16, HPV18, HPV31, HPV33, HPV35,
HPV39, HPV45, HPV51, HPV52, HPV56, HPV58, HPV59,
HPV66, and HPV68 (all HR HPV); and HPV6 and HPV11
(both LR HPV) with MassARRAY (Sequenom, Sandiego,
CA) technique based on the matrix-assisted laser
desorption/ionization time-of flight (MALDI-TOF) mass
spectrometry (MS) [16,17]. All these procedures were
performed in the clinical standard laboratory of BGI
(Beijing Genomics Institute, Shenzhen, China).
ThinPrep cytological test
Another cervical exfoliated cells sample was collected by
cyto-brush (QIAGEN, Valencia, CA) among women with
HPV infection. ThinPrep 2000 (Hologic Inc.) and SurePath
Jing et al. BMC Infectious Diseases 2014, 14:388 Page 2 of 9
http://www.biomedcentral.com/1471-2334/14/388
liquid-based Pap test (BD, USA) were used for the TCT
test which was performed by Kingmed Center for Clinical
Laboratory Corporation (Guangzhou, China). Cytological
slides were read by three cytopathologist. Cervical cell
samples were categorized according to the Bethesda
System (2001) [18,19] as follows: normal; atypical squa-
mous cells of unknown significance (ASCUS); low-grade
squamous intraepithelial neoplasia (LSIL); and high-grade
squamous intraepithelial lesion (HSIL) or worse (i.e., cases
of squamous cell carcinoma were combined with HSIL
cases for the purposes of analysis).
Statistical analysis
The χ2 test was used to compare the differences in HPV
genotype representation for different cytological grades.
Independent predictors for cervical lesions across differ-
ent HPV genotype infection were evaluated via uncondi-
tional logistic regression with odds ratio (ORs) and 95%
confidence intervals (CIs) (LR-HPV: HPV6 or HPV11
as reference). Data analysis was performed using SPSS13.0
(SPSS, Chicago, USA). All statistical tests were two-sided;
P values < 0.05 were considered statistically significant.
Results
Population characteristic
The study participants came from nine cities in
Guangdong’s PRD, China, where is adjacent to Hong
Kong, one of the most prosperous city in China (Figure 1).
Figure 2 shows the flow of study participants. Of the 3226
HPV-positive women included in the analysis, the median
age was 38.0 years, almost all of the women reported 0-1
sexual partners and the mean Years of sexual active life
was 14.4 years, women aged 30-34 years accounted for
the largest proportion (67.0%) of participants. Only 490
(15.5%) women had attended college. A summary of
participants’ characteristics was shown in Table 1. Among
3226 women, 1744 cases (54.1%) was normal cervical
cytology, 632 cases (19.6%) with ASCUS, 237 cases
(7.3%) with LSIL, and 237 cases (7.3%) with HSIL (Table 2).
HPV genotypes and cytology grade
The most common HPV genotypes were HPV16
(20.2%), followed by HPV52 (17.1%), HPV58 (13.2%),
HPV18 (9.5%), HPV6 (7.6%), HPV45 (7.1%), HPV51
(6.7%), HPV66 (6.7%), and HPV39 (6.4%). Across all
cytology grades, HPV16 was the most prevalent type than
that of any other HR-HPV genotype. HPV6, HPV11,
HPV45, and HPV66 were prone to be concentrated in
normal cytology than HSIL. Similar percentages were
detected for each HPV type between ASCUS and LSIL
except for HPV51 and HPV56 in LSIL (Table 3, Figure 3).
The risk factors of HSIL+
In multivariable analyses, women with more than
15 years active sexual life were more likely to be
HSIL + compared to less than 5 years (OR = 3.9, P < 0.001,
95% CI: 1.9 ~ 8.0) (Table 4). Women with high school
education were more likely to be HSIL + compared to
elementary school and below (OR = 2.4, P < 0.01, 95%
CI: 1.4 ~ 4.3). Detection of HSIL + was more common
Figure 1 Nine studied cities (A–I) in the Pearl River Delta region of Guangzhou, China. Geographic locations of the nine cities (A–I) in the
Pearl River Delta region of Guangzhou, China, represented by the study population.
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among women with over 4 times of birth than
women with 0-1 time birth (OR = 3.6, P < 0.001, 95%
CI: 1.7 ~ 7.8). As we can see from Figure 3, HPV16,
HPV33, HPV58, and HPV31 showed high percentage
in HSIL + but low percentage in normal. Overall,
HPV16, HPV58 and HPV33 (especially HPV16 and
HPV33) increased the risk of HSIL + (Figure 3). Notably,
as shown in Table 4, detection of HSIL + was significantly
more common among women with HPV16 (OR = 10.5,
P < 0.001, 95% CI: 3.7 ~ 29.6), HPV33 (OR = 9.1, P < 0.001,
95% CI: 2.8 ~ 29.2), HPV58 (OR= 6.315, P < 0.001, 95%
CI: 2.1 ~ 18.6), HPV31 (OR=4.5, P < 0.05, 95% CI: 1.3~ 15.5),
multiple genotype infection (OR = 3.0, P < 0.01, 95%
CI: 1.7 ~ 14.7) compared with women only with HPV6
or HPV11. Although the proportion of HPV52 infection
were higher in HSIL, there was no significant differ-
ence between cytology grades was observed (HPV52
vs. LR-HPV: OR = 2.9, P > 0.05, 95% CI 0.9 ~ 8.8) (data
were not shown).
Furthermore, of the 237 women with HSIL, the percent-
age of HPV16, HPV31, and HPV59 were significantly
higher among women age above 45 years old than women
less than 45 years old, but there was no HPV11, HPV56, or
HPV68 infection among women with HSIL whom aged
above 45 years old (Figure 4). HPV33 were more common
in women aged 30 ~ 44 years old than other age groups.
HPV58 were more common in women aged 30 or older
than women aged less than 30 years.
Discussion
It is necessary to know the predominant HPV genotypes
associated with cervical lesions with the aim of preventing
cervical cancer. Our study presented the distribution of
HPV genotypes and the association with cytological
characteristics in a population consisted of 3226 women
with HPV positive and an age range between 18 and
68 years in PDR, Southern China.
Findings from our analysis show that HPV16 was the
most predominant genotype in HPV positive women in
PRD, which is similar with the most part of the world.
Besides HPV16, HPV52 and HPV58 were also common
in this study. These results are consistent with studies
confined within part of the same geographical area
[19,20]. Also, HR-HPV genotypes with relatively high
proportion in our study (i.e., HPV16, and HPV58) were
consistent with the study in Asia but different with
Europe, Latin America and Caribbean, Africa, and Oceania
[21]. Notably, percentage of HPV16, HPV31, HPV33, and
HPV58 was significantly higher in women with HSIL or
worse group than other HPV types (Table 3), which is
consistent with the Hou R’s study [22]. All these four HPV
types were characterized as high-risk and carcinogenic
Figure 2 Flow chart of study participants. aAll women were recommended to underwent further treatment according to <2013 ASCCP
Guidelines on Cervical Cancer Screening and Management in US> . our study was shown with internal the dotted-line frame. HPV = human
papillomavirus. TCT = Thinprep cytologic test.
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HPV types [3], which were not only with high prevalence
in the population [20], but also with long duration time
[23-25]. We also found that multiple HPV genotype
infections increased the risk of HSIL compared with
LR-HPV in our study, but it cannot distinguish low-grade
from high-grade cytological lesions [26], thus, we
speculated that infection with specific HPV genotypes
(i.e., HPV16, HPV31, HPV33, and HPV58) may more
likely heightened risks for progression of cervical dysplasia
and carcinoma in the studied population.
Previous studies showed that HPV52 was one of the
predominant genotypes in our study region and also in
other parts of China [19,27,28], but it does not increase
the risk of HSIL in our study (the proportion of HPV33
and HPV58 in HSIL in the present study was signifi-
cantly higher than that of HPV52 which the proportion
was similar to HPV59), which might result from the
method we used, geographic factors, or the polymorphism
of HPV52 contributed to the underestimation of it [29].
The distribution of HPV genotype and risk of cytology
abnormalities in the present study are different from
those in previous studies, which may be the variations
in the study design, specimen types, screening
methods [30]. Our study did not support that the risk of
HSIL + was different in various age groups among women
with HPV infection. But we stratified by age to reduce
confounding and were able to describe the distribution of
HPV genotypes among women with different cytology
grades in various age groups (Additional file 1: Table S1).
In our findings, there is a discrepancy of the HPV
genotype distribution assigned different age groups.
Women less than 30 years old are more likely
infected by HPV52, followed by HPV16, HPV58, and
HPV6. Women aged 30-44years old are more likely
infected by HPV16, HPV52, and women more than
45 years old are more prone to be infected by
HPV58. Interestingly, HPV31 which may increase the
risk of cytology disease were more likely concentrated
in normal compared with HSIL group less than
30 years old (Additional file 1: Table S1) which revealed
that different aged women harbour specific HPV
genotype might with different progressive progression.
Furthermore, women with HPV infection in different
age have different potential of progression [31]. So, it
is of great importance of clarifying the potential role
of specific HPV genotype infection in carcinogenesis
to evaluate the risk and contribution of carcinogenesis
among different aged population in the future. Our data
can move forward the estimate of genotype attribution
Table 1 The demographics of participants





Years of sexual active life
<15 1692 52.4
> = 15 1534 47.6





Elementary school and below (%) 350 9.6
Junior middle school (%) 1368 43.1
High school (%) 1008 31.8
College and above (%) 490 15.5
aNumbers did not always sum to the total due to missing data.
Table 2 Cytology findings founded in 3226 women
studied






aASCUS, atypical squamous cells of undetermined significance; LSIL, low-grade
squamous intraepithelial lesions; HSIL, high-grade squamous intraepithelial lesion.
Table 3 Distribution of HPV genotypes among women
with different cytology grades
Normal ASCUS LSIL HSIL+
n % n % n % n %
HPV6 171 69.5 38 15.5 32 13.0 5 2.0
HPV11 83 69.8 18 15.1 14 11.8 4 3.4
HPV16 302 46.3 137 21.0 106 16.3 107 16.4
HPV18 181 59.0 66 21.5 43 14.0 17 5.5
HPV31 75 49.3 36 23.7 22 14.5 19 12.5
HPV33 59 47.6 18 14.5 26 21.0 21 16.9
HPV35 50 53.2 17 18.1 24 25.5 3 3.2
HPV39 111 53.9 49 23.8 40 19.4 6 2.9
HPV45 140 61.4 42 18.4 38 16.7 8 3.5
HPV51 108 50.2 37 17.2 66 30.7 4 1.9
HPV52 285 51.5 107 19.4 129 23.3 32 5.8
HPV56 52 49.1 18 17.0 33 31.1 3 2.8
HPV58 187 44.0 96 22.6 98 23.1 44 10.4
HPV59 45 58.4 16 20.8 12 15.6 4 5.2
HPV66 133 61.9 32 14.9 45 20.9 5 2.3
HPV68 42 55.3 14 18.4 19 25.0 1 1.3
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Table 4 Multivariate analyse of determinants for cytology grades (HSIL+) among women with human papillomavirus
infection from PDR
Characteristic No. of women with HSIL or Normal detected OR P 95% CI
HPV types
only LR-HPV 125 ref. ref. ref.
HPV16 288 10.49 <0.01 3.72 ~ 29.62**
HPV31 65 4.53 <0.05 1.32 ~ 15.52*
HPV33 60 9.06 <0.01 2.81 ~ 29.21**
HPV58 167 6.32 <0.01 2.14 ~ 18.60**
Multiple genotype infection 206 4.99 <0.01 1.70 ~ 14.71**
Years of sexual active life
0~ 233 ref. ref. ref.
5~ 261 1.89 0.14 0.81 ~ 4.39
10~ 423 2.87 <0.05 1.36 ~ 6.08*
15~ 788 3.87 <0.01 1.87 ~ 8.03**
Education level
Elementary school and below 168 ref. ref. ref.
Junior middle school 723 1.32 0.35 0.74 ~ 2.34
High school 559 2.43 <0.01 1.35 ~ 4.35**
College and above 255 1.31 0.47 0.63 ~ 2.73
Birth times
0-1 943 ref. ref. ref.
2-3 719 1.38 <0.05 0.97 ~ 1.96*
4+ 43 3.62 <0.01 1.68 ~ 7.83**
Note. Totals may be less than stated sample size due to missing data. The multivariable model included data on 1705 women due to missing data on correlates.
HPV = Human papillomavirus, LR-HPV = low-risk human papillomavirus, OR = odds ratio, CI: confidence interval, ref. =referent group. *P < 0.05, **P < 0.01.
Figure 3 Distribution of HPV genotypes among 3226 women with HPV-positive cervical exfoliated cell. The cervical exfoliated cell had a
cytology classification of normal (n = 1744), ASCUS (n = 632), LSIL (n = 613), or HSIL + (n = 237).
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and gain a better understanding of the potential role of
the prevalent genotypes in studied region.
Furthermore, determining the causal attribution of
carcinogenic HPV genotypes to cervical disease is
important in the application of HPV genotypes included
in future screening assays, and in the management and
developing prophylactic vaccines. HPV-based primary
screening is not only more sensitive for earlier detection
of clinically high-grade cervical lesions than cytology [32],
but also is suit for carrying out in lower-resource
countries like China [33]. Early detection of clinically
high-grade cervical lesions caused by specific HPV
types may was a major component of the benefit.
However, HPV-based screening is more inclined to
the detection of lesions with lower potential for pro-
gression and at an earlier age [25,34,35], thus potentially
affecting quality of life. Even high-risk HPV genotypes can
contribute to different progression of cervical disease [11].
The design of our study should be considered
when interpreting our results. Our data are from a
cross-sectional study which was designed to identify
detriments of early-stage cervical disease, so all of
the women were HPV-infected. Indeed, detection of
cytology abnormalities was more common among the
participants with HPV infection in our study compared to
these samples randomly obtained from women in
PRD. We do not believe, however, that study design
solely accounts for the findings observed in our study.
Although future study is needed to confirm the findings
from this study, our data provide valuable initial insight
into the distribution of HPV among PRD women and
suggest that some specific HR-HPV may help explain the
existing cervical cancer disparities in PRD, furthermore,
our results not only give support to the use of HPV
testing, especially including HPV16, HPV58, HPV31,
and HPV33 testing for women aged 30 years and
older but also provided valuable fundamental data to the
future study with the aim of reducing the burden of
cervical cancer, last but not least, these results give us a
hint that may there is great potential use of these HPV
genotypes in improving risk stratification of women with
HPV infection in cervical screening programmes, and in
improving performance and cost-effectiveness of programs
while reducing over treatment and patient anxiety.
There are some limitations in our study. Since we
analyzed a population based on HPV-positive results
from a large cross-sectional study in Guangdong,
women without HPV infection that cause cytological
abnormalities are underrepresented in our population.
Furthermore, the accuracy of the information about
their sexual and reproductive history might impact
the authenticity of this survey.
In summary, the results of this study provide clear
indication of the HPV infections among cytology abnormal
women in the Pearl River Delta region of Guangdong
Province of China, and only a few high-risk HPV genotypes
might be more useful for the screening and monitoring of
pre-cancer lesions.
Conclusions
HPV16, HPV31, HPV33, HPV58, and multiple HPV
genotype infection increased the risk of cytology
Figure 4 Distribution of HPV genotypes among women with HSIL + cytology stratified by age. Of the 237 women diagnosed HSIL, the
percentage of HPV16, HPV31, and HPV59 were significantly higher among women age above 45 years old than women less than 45 years old,
but there was no HPV11, HPV56, or HPV68 infection among women with HSIL whom aged above 45 years old. HPV33 were more common in
women aged 30 ~ 44 years old than other age groups. HPV58 were more common in women aged 30 or older than women aged less
than 30 years.
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abnormalities in Pearl River Delta Region and might
be useful for the screening, preventing, treating, and
monitoring of pre-cancer lesions in southern China.
Additional file
Additional file 1: Table S1. Distribution of HPV genotypes among
different cytology grades stratified by agea.
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